What is HC Wainwright’s Estimate for Heatwurx Q1 Earnings?

Heatwurx Inc. (NASDAQ:PCSA) – Investment analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Heatwurx in a research note issued to investors on Monday, June 30th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of ($0.06) for the quarter. HC Wainwright currently has a “Buy” rating and a $2.00 price target on the stock. The consensus estimate for Heatwurx’s current full-year earnings is ($4.05) per share. HC Wainwright also issued estimates for Heatwurx’s Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.04) EPS and FY2026 earnings at ($0.20) EPS.

Heatwurx (NASDAQ:PCSA) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.47.

Heatwurx Price Performance

NASDAQ PCSA opened at $0.19 on Tuesday. The company has a market cap of $2.24 million, a price-to-earnings ratio of -0.06 and a beta of 1.30. The stock’s fifty day moving average price is $0.26 and its 200 day moving average price is $0.47. Heatwurx has a 1 year low of $0.15 and a 1 year high of $3.10.

About Heatwurx

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.